Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT06326736 Recruiting - Pancreatic Cancer Clinical Trials

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Start date: April 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.

NCT ID: NCT06323291 Recruiting - Pancreatic Cancer Clinical Trials

Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study

Start date: March 8, 2024
Phase: Early Phase 1
Study type: Interventional

This Pilot Study will evaluate a 12-week pilot program that offers digital health coaching for individuals with pancreatic cancer and their caregivers.

NCT ID: NCT06319755 Not yet recruiting - Pancreatic Cancer Clinical Trials

Characteristics of Intestinal Microbiome Following Pancreatic Surgery

Start date: March 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about intestinal microbiome structure and function in individuals who have undergone a pancreatoduodenectomy and compare to healthy matched controls. The primary objectives of the study are: 1. To explore and describe any differences in the gut microbiota especially Shannon diversity index 2. To conduct functional profiling by exploring and describing any differences in functional metabolites produced in the gut in people having had pancreatoduodenectomy greater than 6 months ago compared to healthy matched controls. Participants will be asked to complete the following: - Three-day food, bowel and medication diary (see Protocol appendix 5) - Gastrointestinal Symptom Rating Scale (see Protocol appendix 6) - Quality of life questionnaire (see Protocol appendix 7) - Stool sample test using Microba Insight TradeMark (a small swab is taken from soiled toilet paper, sealed in a room-temperature storage capsule and mailed to the testing laboratory)

NCT ID: NCT06313970 Not yet recruiting - Pancreatic Cancer Clinical Trials

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

NCT ID: NCT06310993 Not yet recruiting - Pancreatic Cancer Clinical Trials

Exercise to Boost Immunity in Advanced Cancer

BICEP
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression

NCT ID: NCT06307080 Recruiting - Pancreatic Cancer Clinical Trials

Clinical Study of Multi-mode Thermal Ablation for the Treatment of Pancreatic Cancer With Liver Metastasis

Start date: October 8, 2023
Phase: N/A
Study type: Interventional

1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.

NCT ID: NCT06298916 Not yet recruiting - Colorectal Cancer Clinical Trials

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

PHANTOM
Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).

NCT ID: NCT06291324 Not yet recruiting - Breast Cancer Clinical Trials

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

Start date: May 2024
Phase:
Study type: Observational

The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.

NCT ID: NCT06289803 Recruiting - Pancreatic Cancer Clinical Trials

The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Aim of the study: To evaluate the value of Probe Confocal Laser Endomicroscopy (PCLE) in surgery for pancreatic tumor. Methods: Patients who are diagnosed with pancreatic tumor based on preoperative radiographic findings and will undergo radical resection are included in this clinical study. PCLE will be used in surgery to identify tumor is malignant or not, and surgeons will decide procedures of surgery based on outcomes of PCLE. In this present study, clinical trials will be divided into two phases. In the first phase, based on the definitive postoperative pathologic diagnosis, characteristic imaging structures that were collected by PCLE will be identified and primary diagnostic imaging criteria for pancreatic cancer would be developed. In the second phase, this criterion will be used for rapid intraoperative diagnosis of pancreatic cancer and predicting status of resection margin. In addition, accuracy of PCLE will be verified based on postoperative pathologic reports.

NCT ID: NCT06283576 Enrolling by invitation - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Initial Detection Via Liquid Biopsy

PANCAID
Start date: March 1, 2024
Phase:
Study type: Observational

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).